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Summary This study assesses the effect of adding continuous-infusion fluorouracil to palliative thoracic radiation therapy (RT) on the rate
and duration of symptom relief in patients with advanced non-small-cell lung cancer (NSCLC). Two hundred eligible patients with NSCLC
were randomized to receive either 20 Gy in five daily fractions as palliation for intrathoracic disease or the same RT with concurrent
continuous infusion of 1 g m-2 day-' fluorouracil for 5 days. Survival, response and rates of symptom relief in the two groups were compared
according to treatment intent, and toxicities were compared according to treatment received. The overall response rate was higher in patients
randomized to the combination (29%) than in patients randomized to RT alone (16%) (P = 0.035). However, there were no significant
differences between the treatment arms in terms of overall or progression-free survival or in palliation of symptoms. Patients treated with RT
plus fluorouracil had significantly more acute toxicity, including nausea and vomiting (P = 0.01), oesophagitis (P = 0.0003), stomatitis (P =
0.0005) and skin reaction (P = 0.003). This study suggests for the first time an interaction between RT and infusional fluorouracil in NSCLC.
Although RT plus fluorouracil resulted in a significantly higher response rate than achieved with RT alone, this did not translate into more
effective palliation. Because the combination produced significantly more toxicity than RT alone, it is not recommended for the palliative
treatment of NSCLC. Nevertheless, these results suggest that opportunities may exist for exploitation of the observed enhancement of anti-
tumour effect in the setting of high-dose radical RT for NSCLC.
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Radiotherapy (RT) is an effective means of palliating thoracic
symptoms in patients with incurable non-small-cell lung cancer
(NSCLC) (Slawson and Scott, 1979). Cough, haemoptysis and
chest pain were relieved in up to 65%, 75% and 85% of patients
respectively in one randomized trial (Medical Research Council
Lung Cancer Working Party, 1991)
It has been assumed that the degree of reduction in tumour size
may correlate with the level of symptom relief and, since one
previous study (Perez et al, 1982) has shown an RT dose-response
relationship in NSCLC, the choice of palliative RT regimen
usually represents a compromise between an adequate dose and an
acceptable length of course of treatment. One strategy by which
the biologically effective dose might be increased without
extending overall treatment time may be to give RT concurrently
with a radiosensitizing drug.
Fluorouracil has been known to enhance radiation-induced cell
killing in vitro for over 30 years (Heidelberger et al, 1958). The
requirements for maximum sensitization by fluorouracil of human
tumour cells were studied by Byfield et al (1982). They observed
that enhancement of cytotoxicity was strongly dependent on both
the concentration offluorouracil and the duration ofexposure, and
that only post-radiation exposure to the drug had a sensitizing
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(as opposed to additive) effect. The optimal conditions could only
be achieved if the fluorouracil were administered by continuous
infusion.
Continuous-infusion fluorouracil has been given concurrently
with RT in a variety of tumours, including head and neck
(Browman et al, 1994), oesophageal (Herskovic et al, 1992), rectal
(O'Connell et al, 1994) and anal cancers (Cummings et al, 1991).
The results of these studies have suggested that combined treat-
ment is more effective than radiotherapy used alone. There has
been only one previously reported randomized trial in which RT
has been compared with RT plus fluorouracil in NSCLC (Carr et
al, 1972). That study failed to reveal any evidence ofan interaction
between drug and radiation in terms ofeither response or effect on
survival; however, the fluorouracil had been administered by bolus
injection, which may be less effective than continuous infusion
(O'Connell et al, 1994). Although there have been previous
reports of fluorouracil given by infusion in conjunction with RT
for NSCLC, these studies were not randomized (Kelly et al, 1989;
Lokich et al, 1989).
The optimum dose and schedule of fluorouracil for concurrent
use with RT for NSCLC are not known. The short half-life (< 15
min) of fluorouracil means that prolonged exposure before and
after fractions of RT can best be achieved with a continuous infu-
sion. Such an approach was shown in rectal carcinoma to be supe-
rior to bolus administration (O'Connell et al, 1994).
This study was designed as a randomized trial, which allowed us
to test two hypotheses: first, that combined RT and infusional fluo-
rouracil might increase response rates in NSCLC in comparison
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with RT alone and, secondly, that increased response rates might
result in longer duration and higher rates of palliation without
increasing overall treatment time.
PATIENTS AND METHODS
Eligibility criteria
To be eligible for randomization, patients had to have histologi-
cally orcytologically proven NSCLC; disease unsuitable foreither
attempted curative resection or radical RT, or recurrent intratho-
racic cancer outside any previously irradiated volume; measurable
or evaluable disease; World Health Organization (WHO) perfor-
mance status grade 0-3 (Miller et al, 1981) with life expectancy of
at least 2 months; adequate bone marrow function with pretreat-
ment haemoglobin > 100 g 1-1, white cell count . 3 x 109 1-1 and
platelet count > 100 x 109 1-1; serum creatinine < 0.15 mmol I-';
adequate liver function with aspartate transaminase less than twice
the upper limit of normal range; and no other serious medical or
psychiatric illness. Before randomization, all patients had to give
written informed consent and the protocol had been approved by
the institutional ethics committees ofthe participating hospitals.
Trial design
The trial was designed as a prospective non-blinded randomized
trial to be conducted at Peter MacCallum Cancer Institute (PMCI).
After the trial had been accruing patients for 3 years, the Royal
Adelaide Hospital (RAH) became involved. Eligible patients were
randomized to receive either RT alone or RT with concurrent fluo-
rouracil with approximately equal probability. Central randomiza-
tion was carried out by the Statistical Centre at PMCI with
stratification for each participating hospital. A permuted block
design was used for randomization at PMCI and a newer adaptive
biased coin design for RAH.
It was originally planned to accrue 300 patients. This sample
size was designed to have a 90% probability of detecting an
increase in local response rate from 40% to 60% or a 50% increase
in the median time to local failure with a two-tailed test at signifi-
cance level 0.05. Planned interim analyses were carried out after
accruing 100 and 200 patients respectively. Following the second
interim analysis, the trial was closed because the acute toxic
effects on the RT plus fluorouracil arm were significantly worse
than on the RT arm, and there was no corresponding significant
benefit in terms ofpalliation ofsymptoms or survival.
Treatment methods
Before treatment, patients were simulated and the films marked so
that the field covered the primary tumour with a 2-cm margin and
the adjacent mediastinum. Anterior and posterior fields were
treated daily to a total midplane dose of 20 Gy in five fractions.
The dose and fractionation schedule were based on a radiotherapy
regimen shown to be effective in the palliation ofbrain (Gelber et
al, 1981) and bone metastases (Tong et al, 1982). Patients random-
ized to receive chemotherapy were given a continuous infusion of
1 g m-2 day-' fluorouracil for 5 days, commencing as soon as
possible on the same day after the first fraction of radiation
(usually within 6 h) and concluding within 24 of the final incre-
ment. Prophylactic antiemetics were not routinely given to patients
randomized to either arm.
Patient assessment
Patients were assessed for treatment-related toxicity during and 1
month after treatment, then at each subsequent visit until acute
toxic effects resolved. Toxicities were graded according to WHO
criteria (Miller et al, 1981). For oesophagitis, for which there are
no WHO criteria, the grades used were: 1, soreness; no medica-
tion; 2, soreness, requests medication; 3, soreness, liquid dietonly;
4, alimentation not possible.
Criteria used for response and progression were those recom-
mended by the WHO (Miller et al, 1981). Tumour size was
measured in two dimensions by a single observer (the treating
radiation oncologist) on pre- and post-treatment plain radiographs
of the chest. If a complete or partial response was based on only
one assessment, it was accepted provided there was no evidence of
relapse within 4 weeks of achieving the response.
Although the presence of symptoms resulting from thoracic
disease was not acriterion foreligibility, the majority ofpatients had
one or more offour major symptoms, namely chestpain (42% ofall
patients), cough (82%), haemoptysis (35%) and dyspnoea (71%).
These four symptoms were assessed before treatment and at each
follow-up visit up to and including the date of progression of the
treated tumour. The symptoms were graded by the clinician
according to a five-point scale from absent (0) to very severe (4).
Performance status (WHO) and weight loss were also documented
before treatment and on each review.
Patients were asked to mark a set ofseven linearanalogue scales
designed to assess their quality oflife both before treatment and at
each review up until progression ofthe treated tumour. Each linear
analogue scale was 100 mm long with no divisions marked. Words
representing the extremes ofpossible responses were written at the
ends ofeach scale with the worst possible quality of life at the left
hand end (0 mm). The questions asked were: in general how well
do you feel? (extremes: very poorly, very well); how is your
mood? (very miserable, very happy); how anxious do you feel?
(very anxious, very relaxed); how well do you sleep? (very poorly,
very well); how good is your appetite? (very poor, very good);
how limited are you in your daily activities? (totally limited, not
limited at all); and, if you compare the benefits of treatment with
the side-effects, how worthwhile was the treatment? (not worth-
while at all, very worthwhile).
Statistical methods
All analyses were carried out according to the randomized treat-
ment arm. Acute toxic effects were also analysed according to the
treatment actually given, and they have been presented in this
paper, as the results were similar to those from the analysis by the
randomized arm. The Wilcoxon rank sum test (two-tailed) was
used to compare the worst grade of acute toxic effects in the two
treatment groups, omitting patients who were not treated or whose
toxic effects were not recorded.
The response rates were calculated as percentages of all
randomized patients with 95 per cent confidence intervals (95%
CI) estimated using the exact probabilities ofthe binomial distrib-
ution. The Yates corrected chi-square test or the Fisher exact test
were used to compare response rates in the two arms.
All patients were followed to 14 February 1994, so this date was
chosen as the close-out date for the analysis, i.e. all subsequent
relapses and deaths were ignored. Only 12 patients were still alive
on this date.
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Overall survival and progression-free survival curves were
measured from the date of randomization and calculated using the
Kaplan-Meier product-limit method. All causes of death were
counted and patients were censored at the close-out date if they
were still alive (overall survival curve) or alive without progression
(progression-free survival curve). Ninety-five per cent confidence
intervals for median survival or progression-free survival were esti-
mated using the Brookmeyer-Crowley method and theMantel-Cox
log-rank test was used to compare patients according to randomized
treatment arm. Multivariate analysis was carried out using the Cox
proportional hazards model and the likelihood ratio test was used to
assess the significance ofthe treatment arm in the model.
The following methods were used to compare the palliative
effects of the two treatments:
1 Using linear interpolation between assessments, the average
grade ofeach symptom was calculated from the date of
randomization until the date ofthe last symptom assessment
on or before progression of the treated tumour or, ifthere had
been no progression, death or the close-out date. The average
grade minus the grade at randomization was also calculated.
Data were available for 89% ofpatients on the RT treatment
arm and 88% on the RT plus fluorouracil arm. Comparison
between treatment arms as carried out using the Wilcoxon rank
sum test, two-tailed. Many patients did not initially have some
of the symptoms being assessed, but they were included in the
comparisons because they had the potential to develop them.
2 The estimated grades on each day were averaged over all
patients still being assessed beyond that day and plotted sepa-
rately by randomization arm for each symptom for the first
year following randomization.
3 From the graphs obtained in (2), it was apparent that the
maximum palliation of symptoms was achieved approximately
8 weeks after randomization. For each patient still being
assessed, the grade ofeach symptom 8 weeks after randomiza-
tion was subtracted from the initial grade and the differences
compared according to treatment arm using the Wilcoxon rank
sum test, two-tailed, omitting patients whose grades were
unknown. Data were available for 64-67% ofpatients on the
RT treatment arm and 77-78% on the RT plus fluorouracil arm,
depending on symptom. This analysis was also done excluding
those patients whose initial symptom grade was zero.
The quality oflife dataforthe first six questions were analysed in a
similar mannerto the symptom data [methods (1) and (2)]. Data were
available for78% ofpatients on the RT treatmentarm and 83% on the
RT plus fluorouracil arm. For the seventh question (how worthwhile
was the treatment) the response of each patient at 1,2,3,6 and 12
months following completion of treatment was obtained by interpo-
lating between responses before and aftereach time point. The values
obtained were averaged over all patients ineach randomized arm who
were still being assessed at that time. The number of patients avail-
able for analysis at each time point varied with the maximum being
53% ofrandomized patients 2 months after treatment.
BMDP Statistical Software was used in the analysis (Dixon, 1992).
RESULTS
Patient population
Between August 1988 and July 1993, 204 patients were random-
ized but four were subsequently excluded because review revealed
Table 1 Patient and disease characteristics according to randomized arm
RT (n = 101) RT + 5-FU (n = 99)
Age at randomization (years)
Median
Range
Sex
Male:female
Histology
Squamous
Non-squamous
Mixed/unspecified
WHO performance status
0
1
2
3
Unknown
Weight loss in past 3 months
No
Yes
Unknown
Disease outside the irradiated area
None
Within chest
Outside chest
Prior treatment
None
Laser bronchoscopy
Surgery
Radiation to other sites + surgery
Pretreatment chest pain
None
Mild
Moderate
Severe
Unknown
Pretreatment cough
None
Mild
Moderate
Severe
Very severe
Unknown
Pretreatment haemoptysis
None
Mild
Moderate
Severe
Unknown
Pretreatment dyspnoea
None
Mild
Moderate
Severe
Very severe
Unknown
67
40-91
67
42-86
Percentage of patients
70:30 79:21
49
49
3
51
41
7
0
40
60
0
49
16
36
61
38
1
2
47
40
7
3
35
63
2
56
11
33
91
4
5
0
54
27
15
3
1
16
44
32
8
1
0
89
4
5
2
59
20
13
5
3
16
42
32
5
0
4
68
25
4
0
3
27
23
39
7
0
3
59
31
9
1
0
28
28
31
13
1
0
they had not met the eligibility criteria at randomization. The
reasons for exclusion were small-cell carcinoma on pathology
review (one patient), leiomyosarcoma at autopsy (one),
oesophageal primary on review of radiology (one) and renal
failure with incorrectly recorded serum creatinine (one). This left
200 patients eligible for analysis. Ofthese, 96% were treated at the
Peter MacCallum Cancer Institute and 4% at the Royal Adelaide
Hospital.
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Table 2 Acute toxic effects according to treatment given
RT (n=106) RT 5-FU (n= 90)
Worst grade No. %a No. %a
Nausea and vomiting 0 57 58 35 39
1 24 24 28 31
2 15 15 19 21
3 2 2 6 7
4 1 1 1 1
Unknown 7 1
Oesophagitis 0 59 60 31 35
1 23 23 27 30
2 14 14 20 22
3 3 3 11 12
Unknown 7 1
Skin reaction 0 83 86 60 68
1 13 14 27 31
2 0 0 1 1
Unknown 10 2
Stomatitis 0 95 96 71 80
1 3 3 7 8
2 1 1 9 10
3 0 0 2 2
Unknown 7 1
aPercentage of patients with known values.
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Figure 2 Progression-free survival by randomized treatment arm
Table 3 Best response of treated tumour according to randomized arm
RT RT + 5FU
Complete response 3 1
Partial response 13 28
Stable disease 45 47
Progressive disease 21 9
Not evaluable 19 14
Total 101 99
Reason not evaluable
Not treated 0 4
Early death (.7 weeks after RT) 10 4
Non-evaluable radiograph (fibrosis, effusion) 5 5
Patient did not return or withdrew consent 3 1
No pretreatment radiograph for comparison 1 0
Total 19 14
Table 1 lists the characteristics ofeligible patients atrandomiza-
tion. Pretreatment characteristics were reasonably balanced
between the two arms except for the histology distribution (49%
squamous cell carcinomas on RT compared with 61% on RT plus
fluorouracil, P = 0.15). Staging for the presence of distant metas-
tases was not routinely done because ofthe palliative nature ofthe
treatment. Nevertheless, it can be seen that approximately half of
the patients in each arm were known to have metastatic disease,
either within or outside the thorax.
Treatment
Of 101 patients randomized to RT alone, 99 (98%) received treat-
ment as planned and two had breaks in treatment (one of these
ceased RT after 16 Gy). Of 99 patients randomized to RT plus
fluorouracil, 81 (82%) received treatment as planned, fourpatients
received no treatment at all, five patients were treated with RT
alone, three received less than the full dose of RT or fluorouracil
and six patients experienced 1-day breaks or delays to the planned
schedule of administration of combined treatment. Because
patients randomized to RT alone were more likely to start treat-
ment in the middle ofthe week, the duration oftreatment was 6-8
days rather than 5 days in 29% of patients, compared with 9% of
patients randomized to RT plus fluorouracil, since no treatment
was given on Sundays.
Acute toxicity
For the toxicity analysis, patients have been grouped according to
treatment received, and four patients who were not treated have
been omitted. Hence, comparisons have been made between 106
patients given RT alone and 90 patients given RT plus fluorouracil.
There were no significant differences in haematological toxicity
between the groups, and no instances ofgrade 2,3 or4 neutropenia
or thrombocytopenia were recorded. Patients treated with the
combination had significantly more nausea and vomiting (P =
0.010), oesophagitis (P = 0.0003), skin reaction (P = 0.003) and
stomatitis (P = 0.0005) than patients treated with RT alone (Table
2). No other toxic effects differed significantly between the two
treatment groups (P> 0.05).
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Table 4 Palliation of symptoms according to randomization arm
RT(n=101) RT +5-FU(n=99)
Average minus initial grade No. %a No. %a
Chest pain (P= 0.48) Improved 19 21 22 25
No change 63 70 57 66
Worse 8 9 8 9
Unknown 11 12
Cough (P= 0.48) Improved 34 38 37 43
No change 46 51 43 49
Worse 10 11 7 8
Unknown 11 12
Haemoptysis (P= 0.24) Improved 27 30 25 29
No change 60 67 61 70
Worse 3 3 1 1
Unknown 11 12
Dyspnoea (P = 0.25) Improved 24 27 28 33
No change 56 62 48 56
Worse 10 11 10 12
Unknown 11 13
aPercentage of patients with known values. Improved, improvement of at least 0.5 grade compared with initial grade; worse, deterioration of
more than 0.5 grade compared with initial grade; no change, neither better nor worse, including patients who never had the symptom. P-values
are for comparisons between the randomization arms using the Wilcoxon rank sum test on actual average minus initial grades, i.e. not on the
grouped data.
Table 5 Palliation of symptoms according to randomization arm (omitting patients with grade 0 initially)
Average minus initial grade No. %a No. %a
RT(n=46) RT+5-FU(n=41)
Chest pain (P= 0.28) Improved 19 51 22 65
Nochange 16 43 10 29
Worse 2 5 2 6
Unknown 9 7
RT (85) RT + 5-FU (83)
Cough (P= 0.48) Improved 34 45 37 51
No change 39 51 32 44
Worse 3 4 4 5
Unknown 9 10
RT (41) RT + 5-FU (32)
Haemoptysis (P= 0.61) Improved 27 73 25 93
No change 9 24 2 7
Worse 1 3 0 0
Unknown 4 5
RT (73) RT + 5-FU (72)
Dyspnoea (P = 0.21) Improved 24 37 28 45
No change 37 57 30 48
Worse 4 6 4 6
Unknown 8 10
aPercentage of patients with known values. Improved, improvement of at least 0.5 grade compared with initial grade; worse, deterioration of
more than 0.5 grade compared with initial grade; no change, neither better nor worse. P-values are for comparisons between the
randomization arms using the Wilcoxon rank sum test on actual average minus initial grades, i.e. not on the grouped data.
Other instances of grade 3 or 4 toxicity included diarrhoea in
one patient given RT plus fluorouracil, pulmonary toxicity in two
patients given RT alone, spinal cord injury in one patient given RT
plus fluorouracil and fatigue/lethargy in one patient each given RT
alone and RT plus fluorouracil, but for these toxicities there were
no significant differences between the groups. One patient treated
with the combination developed moderate angina requiring
discontinuation offluorouracil.
Response and survival
The best response of the treated tumour, as measured from plain
radiographs, was recorded according to the intention to treat as in
Table 3. The overall response rate for patients randomized to the
combination was 29% (95% CI 21-39%), which was significantly
higher than the response rate of 16% (95% CI 9-24%) for patients
randomized to RT alone (P = 0.035).
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Figure 4 Haemoptysis by randomized treatment arm. Higher grade = worse
haemoptysis
Table 6 Quality of life according to randomization arm
RT(n 101) RT 5-FU (n 99)
Average minus initial level No. No.
In general, howwell doyou feel? Improved 23 29 20 24
(P=0.47) Nochange 35 44 35 43
Worse 22 28 27 33
Unknown 21 17
How isyourmood? Improved 24 30 21 26
(P=0.51) Nochange 36 46 41 50
Worse 19 24 20 24
Unknown 22 17
How anxious doyou feel? Improved 27 34 26 32
(P= 00.1) Nochange 42 53 36 44
Worse 10 13 20 24
Unknown 22 17
How well doyousleep? Improved 23 29 23 28
(P=0.57) Nochange 35 44 35 43
Worse 21 27 24 29
Unknown 22 17
Howgood isyourappetite? Improved 27 34 23 28
(P =0.39) Nochange 32 41 32 39
Worse 20 25 27 33
Unknown 22 17
How limited areyou inyour Improved 23 29 15 18
dailyactivities? Nochange 35 44 40 49
(P=0.30) Worse 21 27 27 33
Unknown 22 17
aPercentageofpatientswithknownvalues.Improved,improvementofatleast10mmcomparedwithinitiallevel; worse,deterioration of morethan 10 mm
comparedwithinitiallevel;nochange,neitherbetternorworse.P-valuesareforcomparisonsbetweentherandomization armsusingtheWilcoxon rank sum
test on actual average minus initial levels, i.e. not on the grouped data.
By the close-out date, 92% of patients randomized to RT and
96% of patients randomized to RT plus fluorouracil had died.
Survival measured from the date of randomization for all 200
patients according to treatment intent is shown in Figure 1. The
estimated median survival for patients randomized to RT was 6.0
months (95% CI 5.0-7.9 months) with an estimated 26% alive at1
year and 4% at 2 years. The estimated median survival for patients
randomized to RT plus fluorouracil was 6.8 months (95% CI
5.8-8.0 months) with an estimated 26% alive at year and 9% at 2
years. There was no significant difference in survival between the
two treatment arms (P = 0.36).
Multivariate analysis, adjusting for potential prognostic factors,
namely pretreatment performance status grade 2 or 3, weight loss,
non-squamous histology and presence of disease outside the irra-
diated area, confirmed that the randomized treatment arm had no
significant influence on survival (P = 0.33).
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Progression-free survival is shown in Figure 2. The estimated
median progression-free survival for patients randomized to RT
was 3.0 months (95% CI 2.3-3.4 months) with an estimated 6%
alive without progression at1 year. The estimated median progres-
sion-free survival for patients randomized to RT plus fluorouracil
was 3.8 months (95% CI 3.2-4.2 months) with an estimated 9%
alive without progression at 1 year. The difference between arms
was not statistically significant (P = 0.073). This result was
confirmed after adjustment for the four potential prognostic factors
in a multivariate model (P = 0.086).
Palliation of symptoms
For each of the four symptoms, there were no significant differ-
ences between the two randomization arms in initial grade (P2
0.09), average grade following randomization (P . 0.17), average
minus initial grades (P2 0.24) or 8-week minus initial grades (P .
0.13). Table 4 shows the average minus initial grades according to
randomization arm. Table 5 shows the same results after excluding
patients who did not have the symptom initially.
Figure 3 shows the average grade of haemoptysis plotted over
time according to initial grade, and Figure 4 shows the average
grade according to randomized treatment arm. Similar plots (not
shown) were prepared for the other three symptoms assessed.
The average grade of symptoms was lower after randomization
for 45 patients who achieved complete or partial response
compared with 122 patients who had stable or progressive disease
(chest pain P = 0.022, cough P = 0.0006, haemoptysis P = 0.055,
and dyspnoea P = 0.0098). However, when the initial symptom
grade was subtracted from the average grade post-randomization,
there were no significant differences between responders and non-
responders (P .0.065).
Quality of life
Table 6 shows the changes in responses to each ofthe six quality of
life questions. There were no significant differences between
randomization arms in the average minus initial levels recorded for
any of these questions (P . 0.11). There were no significant differ-
ences between arms with respect to whether the patients consid-
ered their treatment to be worthwhile at any of the five specified
times following completion of treatment (P .0.15).
DISCUSSION
One previous randomized comparison of RT v's combined RT and
bolus fluorouracil in NSCLC failed to reveal any evidence of an
interaction between drug and radiation either in terms of response
or effect on survival (Carr et al, 1972). Since then, the feasibility of
delivering fluorouracil by continuous infusion concurrently with
both palliative (Kelly et al, 1989) and radical RT (Lokich et al,
1989) for NSCLC has been established but, because these were
both single-arm studies, no conclusions were possible with regard
to the effects of combined treatment on response rates, survival
and toxicity.
In the current study, combined treatment using infusional fluo-
rouracil increased the local response rate. There was also a non-
significant increase in the duration of progression-free survival
with the combined treatment. Our results thus suggest, for the first
time, an interaction between RT and infusional fluorouracil in
NSCLC but, because the trial did not contain a chemotherapy-only
arm, we are unable to say whether the interaction is additive or
synergistic. The limited information available on the response of
NSCLC to infusional fluorouracil as a single agent suggests that it
has low activity - 8% response rate in one phaseII study (Citron et
al, 1992). In our trial, the difference in response between treatment
arms was 13%.
We also observed an increase in acute toxicities associated with
the combination compared with RT alone. It is possible that a
similar outcome (increased response rates and increased toxicities)
may have been achieved simply by increasing the total radiation
dose, in which case there has been no therapeutic gain. The acute
toxicities were tolerable (grades 1-2) in the majority of patients,
but of particular concern was the development of spinal cord
injury in one patient shortly after the completion of combination
treatment. The clinical features and magnetic resonance imaging
(MRI) scan appearances were consistent with radiation
myelopathy; however, such an isolated event suggests that the
patient may have been genetically susceptible to radiation injury
and any role of fluorouracil in the development of this complica-
tion remains speculative.
This study has confirmed that RT is an effective means of
relieving symptoms, especially chest pain and haemoptysis, in
patients with advanced NSCLC. Unlike previous studies of pallia-
tive RT in NSCLC, we have included in the analyses those patients
who did not have the symptom initially. A few of these patients
subsequently went on to develop new symptoms in spite of RT,
and we felt that account should be taken of what are effectively
treatment failures. Using this method, the rates of palliation appear
inferior to those reported in the British Medical Research Council
(MRC) studies, but when only those patients with the symptom
present initially are analysed (Table 5), the rates of symptom relief
in this and the MRC studies are similar. For example, cough,
haemoptysis and chest pain improved in 48%, 81% and 58%,
respectively, of patients in this study compared with 52%, 73%
and 66% of patients with corresponding symptoms in one of the
MRC trials (Medical Research Council Lung Cancer Working
Party, 1992).
The relationship, if any, between objective response rate and
palliation success in NSCLC is unclear. Although a dose-objective
response relationship was evident in a RTOG study of definitive
radical RT (Perez et al, 1982), a similar relationship was not found
in a palliative study conducted by the same group (Simpson et al,
1985), nor was increasing dose associated with higher rates of
symptom relief. None of the three MRC studies (Medical Research
Council Lung Cancer Working Party, 1991, 1992; British Medical
Research Council Lung Cancer Working Party, 1994) of palliative
RT has shown differences in palliation between several different
fractionation regimens, although higher doses were associated
with more severe oesophagitis in two of the studies (Medical
Research Council Lung Cancer Working Party, 1992; British
Medical Research Council Lung Cancer Working Party, 1994).
and with longer survival in one (British Medical Research Council
Lung Cancer Working Party, 1994). In a recently reported random-
ized trial from South Africa, a higher-dose regimen was not asso-
ciated with higher symptom or objective tumour response,
although it did produce more severe oesophagitis (Abratt et al,
1995). Our study is in keeping with these observations in that the
addition of infusional fluorouracil, although increasing the
response rate, did not result in significantly better palliation or
quality oflife. The reasons for this are unclear, but one could spec-
ulate that current techniques for assessing palliation success are
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not sufficiently refined to detect treatment benefits. Alternatively,
the doses used in the palliative range for NSCLC may lie below
the threshold above which any sigmoid dose-response relationship
for symptom relief becomes evident. Absence of a clear dose-
response relationship has been consistently observed in other
palliative situations, including the treatment of bone (Tong et al,
1982) and brain metastases (Gelber et al, 1981).
Whatever benefits may have resulted from the use of the combi-
nation, e.g. slightly longer progression-free survival in patients with
limited disease, have been at the cost of greater toxicity and,
although the toxicity was relatively mild, we are unable to recom-
mend the combination regimen as palliation for NSCLC. The
observed butpreviously unreported interaction between fluorouracil
and radiation in NSCLC may nevertheless provide opportunities for
further study in patients receiving radical RT for NSCLC.
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